Titre Long Term Follow-Up of Participants Exposed to GSK3377794 (NY-ESO-1c259 T), a Genetically Engineered NY-ESO-1 Specific T Cell Receptor
Protocole ID GSK 208750
ClinicalTrials.gov ID NCT03391778
Type(s) de cancer Autre
Phase Autres
Institution CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
   PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
      5415 boul. de l'Assomption, Montréal, QC, H1T2M4
Ville Montréal
Investigateur(trice) principal(e) Dr Jonathan Noujaim
Coordonnateur(trice) Olivier Cormier
514-252-3400 poste 5966
Statut Actif en recrutement
Critètes d'éligibilité
  • Subjects who have received at least one dose of GSK3377794 in the interventional study.
  • Subjects who have either completed the interventional study or have withdrawn from it.
  • Male or Female subjects.
  • Capable of giving signed informed consent prior to the study participation.
Critètes d'exclusion
  •  None